Structural genomics and drug discovery
- PMID: 17488474
- PMCID: PMC3822824
- DOI: 10.1111/j.1582-4934.2007.00028.x
Structural genomics and drug discovery
Abstract
Structure determination has already proven useful for lead optimization and direct drug design. The number of high-resolution structures available in public databases today exceeds 30,000 and will definitely aid in structure-based drug design. Structural genomics approaches covering whole genomes, topologically similar proteins or gene families are great assets for further progress in the development of new drugs. However, membrane proteins representing 70% of current drug targets are poorly characterized structurally. The problems have been related to difficulties in obtaining large amount of recombinant membrane proteins as well as their purification and structure determination. Structural genomics has proven successful in developing new methods in areas from expression to structure determination by studying a large number of target proteins in parallel.
References
-
- Lombardino JG, Love JA., III The role of the medicinal chemistry in drug discovery – then and now. Nat Rev Drug Discov. 2004;3:853–62. - PubMed
-
- Lundstrom K. The future of G protein-coupled receptors as targets in drug discovery. Idrugs. 2005;8:909–13. - PubMed
-
- Helenius A, Simons K. Solubilization of membranes by detergents. Biochim Biophys Acta. 1975;415:29–79. - PubMed
-
- Loll PJ. Membrane protein structural biology: the high throughput challenge. J Struct Biol. 2003;142:144–53. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
